Polio Vaccine Pioneer Dies

Julius Youngner collaborated with Jonas Salk on the polio vaccine, and later identified interferon gamma and contributed to an equine influenza vaccine.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

UNIVERSITY OF PITTSBURGHJulius Youngner, whose research with Jonas Salk at the University of Pittsburgh contributed to the polio vaccine, died at his home in Pittsburgh on April 27. He was 96.

Among Youngner’s contributions were the development of a cell culture technique that allowed for scaling up production of the vaccine and the invention of a method for inactivating the virus.

“Dr. Youngner made monumental contributions to the field of virology,” Vincent Racaniello, a microbiologist at Columbia University, said in a statement. “For most, simply working with Jonas Salk on the development of the polio vaccine would be enough for a career; he also made important contributions to our understanding of the antiviral roles of interferon, cell culture, and other vaccines.”

Born in New York, Youngner studied English and biology at New York University, and then earned his masters and doctoral degrees from the University of Michigan. After working on the Manhattan Project with the US ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies